Chronic pancreatitis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Chronic pancreatitis is a multifactorial, fibroinflammatory syndrome in which repetitive episodes of pancreatic inflammation lead to extensive fibrotic tissue replacement, resulting in chronic pain, exocrine and endocrine pancreatic insufficiency, reduced quality of life, and a shorter life expectancy.

Etiology-

The TIGAR-O classification system, identifies 6 major etiologies for Chronic pancreatitis :  toxic/metabolic (T), idiopathic (I), genetic (G), autoimmune (A), recurrent and severe acute pancreatitis (R), and obstruction (O).

 

Epidemiology-

The prevalence between 2001 and 2013 of adult US Americans with health insurance (48·67 million) was 25·4–98·7 per 100000 people, depending on search criteria, with a small increase in the male to female ratio of 1·05 (75·2 men vs 71·8 women per 100000 people), peaking in patients aged 46–55 years.16 The incidence is estimated to be four to five new cases per 100000 per year, thus confirming data from a comprehensive population-based study from Minnesota.

The competitive landscape of Chronic pancreatitis includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Chronic pancreatitis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic pancreatitis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Readmore: Chronic pancreatitis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset                           Company                                             Stage

1          Human Secretin             ChiRhoClin, Inc.                                    Phase 2

2          NI-03                            Kangen Pharmaceuticals, Inc                 Phase 2

3          MS1819-SD                  AzurRx SAS                                          Phase 2

4          Reparixin                      Dompé Farmaceutici S.p.A                    Phase 2

5          Triamcinolone               TAP Pharmaceutical Products Inc.            Phase 3

6          Pioglitazone                  Takeda Pharmaceuticals North America, Inc.       Phase 2

7          Creon36™                    AbbVie                                                  Phase 2

8          Viokase® 16                 Forest Laboratories                               Phase 3